IN2013MN01582A - - Google Patents

Download PDF

Info

Publication number
IN2013MN01582A
IN2013MN01582A IN1582MUN2013A IN2013MN01582A IN 2013MN01582 A IN2013MN01582 A IN 2013MN01582A IN 1582MUN2013 A IN1582MUN2013 A IN 1582MUN2013A IN 2013MN01582 A IN2013MN01582 A IN 2013MN01582A
Authority
IN
India
Prior art keywords
relates
present
short peptides
properties
clinical
Prior art date
Application number
Other languages
English (en)
Inventor
Josef Mograbi
Daphne Atlas
Shoshana Keynan
Original Assignee
Oneday Biotech And Pharma Ltd
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oneday Biotech And Pharma Ltd, Yissum Res Dev Co filed Critical Oneday Biotech And Pharma Ltd
Publication of IN2013MN01582A publication Critical patent/IN2013MN01582A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q90/00—Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/51—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
IN1582MUN2013 2011-01-20 2012-01-19 IN2013MN01582A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434454P 2011-01-20 2011-01-20
US201161469138P 2011-03-30 2011-03-30
PCT/IL2012/000032 WO2012098546A2 (en) 2011-01-20 2012-01-19 Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof

Publications (1)

Publication Number Publication Date
IN2013MN01582A true IN2013MN01582A (ja) 2015-06-12

Family

ID=45755445

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1582MUN2013 IN2013MN01582A (ja) 2011-01-20 2012-01-19

Country Status (8)

Country Link
US (3) US8802635B2 (ja)
EP (2) EP3121189A1 (ja)
JP (1) JP5943433B2 (ja)
CN (2) CN103415532B (ja)
AU (1) AU2012208283B2 (ja)
CA (1) CA2825273A1 (ja)
IN (1) IN2013MN01582A (ja)
WO (1) WO2012098546A2 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2879019A1 (en) * 2012-07-23 2014-01-30 Oneday - Biotech And Pharma Ltd. Glutathione-elevating compositions and uses thereof
EP2877194A4 (en) 2012-07-25 2016-03-16 Oneday Biotech And Pharma Ltd Compositions and methods for increasing carnitine concentration in muscle tissue
CN104840940B (zh) * 2013-08-10 2018-04-10 李�昊 一种抗菌止痒消炎消肿去疤痕的短肽的应用
EP3674297A1 (en) 2013-11-08 2020-07-01 Promentis Pharmaceuticals, Inc. Substituted n-acetyl-l-cysteine derivatives and related compounds
WO2015084875A1 (en) * 2013-12-02 2015-06-11 Stealth Peptides International, Inc. Compositions and methods for treating vitiligo
WO2015118546A1 (en) * 2014-02-10 2015-08-13 Oneday - Biotech And Pharma Ltd. Mucolytic compositions and uses thereof
US9464111B2 (en) * 2014-06-26 2016-10-11 L'oreal Short peptides and a method of use as an antioxidant
JP6742312B2 (ja) * 2014-08-05 2020-08-19 アマンタン・エクスペール 皮膚保護組成物
JP6533723B2 (ja) * 2015-09-11 2019-06-19 キユーピー株式会社 抗酸化剤
CN105254714B (zh) * 2015-10-16 2019-09-10 中国农业大学 一种源自酪蛋白的抗氧化肽及应用
CN106432014B (zh) * 2016-09-05 2019-08-16 中国医学科学院放射医学研究所 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用
CN106749525B (zh) * 2016-12-07 2020-01-07 南京财经大学 一种小肽及其应用
KR101943081B1 (ko) * 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
KR102293250B1 (ko) * 2017-09-18 2021-08-26 애니젠 주식회사 활성물질-헥사펩타이드 복합체 및 이를 포함하는 화장료 조성물
CN108484738B (zh) * 2018-03-28 2022-03-15 中国人民解放军军事科学院军事医学研究院 辐抗肽突变蛋白及其制备与纯化方法
WO2021230393A1 (ko) * 2020-05-12 2021-11-18 주식회사 카인사이언스 염증성 피부질환 치료용 펩타이드 및 이의 용도
CN112608966B (zh) * 2020-12-31 2023-05-23 华南理工大学 一种超声辅助矿物质螯合杏仁肽及其制备方法和应用
CN114041603A (zh) * 2021-11-09 2022-02-15 中国农业大学 肽-锌螯合物在抗过敏产品中的应用
WO2024011300A1 (en) * 2022-07-13 2024-01-18 L'oreal Modified peptides, composition, method for inhibiting contraction of muscle cells, method for improving the skin and use of a modified peptide

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
WO2002064091A2 (en) * 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5985261A (en) * 1996-06-28 1999-11-16 National Jewish Medical And Research Center Use of thioredoxin-like molecules for induction of MnSOD to treat oxidative damage
US5928926A (en) * 1996-07-01 1999-07-27 Research Development Foundation Isolation and cloning of the human ARSA-I gene and uses thereof
US5874468A (en) 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US6369106B1 (en) 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US5889055A (en) 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US6627746B1 (en) * 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
AU4411499A (en) 1998-06-05 1999-12-20 Human Genome Sciences, Inc. Connective tissue growth factor-4
US8252309B2 (en) 2000-04-04 2012-08-28 Sigma-Tau Industrie Farmaceutiche Riunite Spa Dietary supplement energy-providing to skeletal muscles
US20030109457A1 (en) * 2001-10-25 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
GB2368339B (en) * 2000-10-26 2002-09-18 Yissum Res Dev Co Complex incorporating a plurality of antioxidants
GB0108491D0 (en) * 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
US6903136B2 (en) 2002-04-22 2005-06-07 Experimental And Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
US7195766B2 (en) 2002-09-10 2007-03-27 National Jewish Medical And Research Center Product and process for liquefaction of mucus or sputum
US7361747B2 (en) * 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
JP2007527503A (ja) * 2003-06-17 2007-09-27 プロノタ・エヌブイ ペプチドコンボ及びそれらの使用
ITRM20040066A1 (it) * 2004-02-09 2004-05-09 Consiglio Nazionale Ricerche Metodo di identificazione di peptidi antigenici e relativo uso per la preparazione di un vaccino anti hiv-1.
WO2005123108A2 (en) 2004-06-09 2005-12-29 William Feinstein Advanced vitamins and protein based nutritional supplements
AU2006262020B8 (en) * 2005-06-24 2011-02-17 Recombinetics, Inc. Using cytosine deaminases to diminish retroelement transfer from pigs to humans
WO2007144979A1 (ja) * 2006-06-12 2007-12-21 Vexon, Inc. ペプチド誘導体
US7713937B2 (en) * 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US20090285912A1 (en) 2008-05-16 2009-11-19 Ramiro Rodriquez Food Supplement and Method for Enhancing Athletic Performance
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
CA2879019A1 (en) 2012-07-23 2014-01-30 Oneday - Biotech And Pharma Ltd. Glutathione-elevating compositions and uses thereof
EP2877194A4 (en) 2012-07-25 2016-03-16 Oneday Biotech And Pharma Ltd Compositions and methods for increasing carnitine concentration in muscle tissue

Also Published As

Publication number Publication date
AU2012208283A1 (en) 2013-08-29
AU2012208283B2 (en) 2017-01-05
US20150218211A1 (en) 2015-08-06
WO2012098546A2 (en) 2012-07-26
WO2012098546A8 (en) 2012-09-20
US9034824B2 (en) 2015-05-19
US8802635B2 (en) 2014-08-12
JP5943433B2 (ja) 2016-07-05
EP2665742B1 (en) 2016-04-20
US20130316942A1 (en) 2013-11-28
CN103415532A (zh) 2013-11-27
CA2825273A1 (en) 2012-07-26
CN105837659A (zh) 2016-08-10
AU2012208283A8 (en) 2013-09-12
US9617301B2 (en) 2017-04-11
US20140315787A1 (en) 2014-10-23
CN103415532B (zh) 2016-05-04
EP2665742A2 (en) 2013-11-27
WO2012098546A3 (en) 2013-01-03
JP2014504598A (ja) 2014-02-24
EP3121189A1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
IN2013MN01582A (ja)
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
MX347165B (es) Composicion efervescente en forma solida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales.
IN2014DN08721A (ja)
IN2015DN00127A (ja)
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EP2556163A4 (en) GLYCANES WITH HIGH MANOQUE CONTENT
WO2015054642A3 (en) Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
EP3043771A4 (en) Cosmetic uses of molded placental compositions
IN2012MU03723A (ja)
IN2014DN07691A (ja)
IN2013MU03641A (ja)
IN2015DN01524A (ja)
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
EP2819685A4 (en) METHOD AND COMPOSITIONS FOR INCREASING OPTICAL PERFORMANCE
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
MX2015017413A (es) Metodos para analizar composiciones de cisteamina.
IN2013MU03768A (ja)
IN2013MU01927A (ja)
IN2013CH05770A (ja)